Glucagon-like peptide-1 receptor agonists mimic and greatly extend the action of the endogenous incretin hormone glucagon-like peptide-1. By binding the glucagon-like peptide-1 receptor — a G protein-coupled receptor expressed in pancreatic beta cells, the central nervous system, the gastrointestinal tract, the heart, and the kidney — they produce a remarkably broad range of effects that extend well beyond glucose lowering.

The glucagon-like peptide-1 receptor signals through Gs protein coupling, activating adenylyl cyclase, raising intracellular cyclic adenosine monophosphate, and activating protein kinase A. In pancreatic beta cells this amplifies glucose-stimulated insulin secretion — critically, in a glucose-dependent manner, meaning insulin secretion increases only when glucose is elevated and diminishes as glucose normalizes. The same signaling pathway simultaneously suppresses glucagon secretion from alpha cells when glucose is elevated. These two complementary effects — more insulin when glucose is high, less glucagon throughout — produce effective glucose lowering with very low monotherapy hypoglycemia risk.

Beyond the pancreas, glucagon-like peptide-1 receptors in the hypothalamus and brainstem reduce appetite and increase satiety, producing the substantial weight loss that distinguishes this class from most other antihyperglycemic agents. Glucagon-like peptide-1 receptor activation also slows gastric emptying, which reduces postprandial glucose excursions but also contributes to nausea. In the heart and vasculature, glucagon-like peptide-1 receptor signaling reduces inflammation, oxidative stress, and atherosclerotic plaque progression through mechanisms that appear partly independent of glucose lowering, forming the biological basis for the cardiovascular outcome trial benefits seen with several agents.

Multiple large cardiovascular outcome trials have demonstrated that certain glucagon-like peptide-1 receptor agonists reduce major adverse cardiovascular events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease or high cardiovascular risk. This is a class effect seen predominantly with the human glucagon-like peptide-1 analog subclass — not with the shorter-acting exendin-based agents.

The LEADER trial (liraglutide versus placebo, over 9000 patients with high cardiovascular risk) demonstrated a significant 13 percent reduction in major adverse cardiovascular events — a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke — driven primarily by a reduction in cardiovascular mortality. SUSTAIN-6 (semaglutide) showed a 26 percent reduction in major adverse cardiovascular events, with stroke reduction being particularly prominent. REWIND (dulaglutide) demonstrated benefit in a broader population that included patients without prior cardiovascular events, suggesting the benefit may extend to primary prevention in high-risk patients.

The ELIXA trial (lixisenatide) and EXSCEL trial (exenatide once weekly) showed cardiovascular neutrality — no benefit, no harm. This pattern supports the view that cardiovascular benefit is specific to the human glucagon-like peptide-1 analog subclass, possibly reflecting greater receptor engagement duration or structural differences in receptor activation. The mechanism of cardiovascular benefit is incompletely understood but involves anti-inflammatory and antiatherosclerotic effects beyond glucose lowering.

Glucagon-like peptide-1 receptor agonists have moved from second- or third-line agents to first-line therapy — ahead of or alongside metformin — in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease, high cardiovascular risk, or obesity. Their combination of glycemic efficacy, weight loss, and cardiovascular benefit makes them among the most versatile agents in the diabetes pharmacopeia.

Current American Diabetes Association guidelines recommend a glucagon-like peptide-1 receptor agonist with proven cardiovascular benefit as the preferred add-on when cardiovascular disease is present, regardless of glycated hemoglobin. For patients whose primary goal is weight loss, semaglutide and liraglutide at higher approved doses produce 10 to 15 percent body weight reduction and are approved for obesity management independent of diabetes. Combining a glucagon-like peptide-1 receptor agonist with a sodium-glucose cotransporter-2 inhibitor is an evidence-based and increasingly used combination that provides complementary cardiovascular and renal protection.

Glucagon-like peptide-1 receptor agonists can be combined with basal insulin; the combination reduces glycated hemoglobin more than either agent alone and attenuates the weight gain associated with insulin initiation. Fixed-ratio combination products (insulin degludec plus liraglutide as Xultophy, insulin glargine plus lixisenatide as Soliqua) simplify regimens. When adding a glucagon-like peptide-1 receptor agonist to a sulfonylurea regimen, the sulfonylurea dose should be reduced by 25 to 50 percent to reduce hypoglycemia risk.